A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
- DRUG: Itepekimab (SAR440340)
- DRUG: Placebo
- DRUG: Mometasone furoate nasal spray (MFNS)
Sponsor
Sanofi
Collaborators